More than 100 industry players and over 60 non-industry players currently claim to manufacture (Root

Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers may need to strengthen their capabilities and expand available capacity. In this context, automation is expected to be a key enabler within the cell therapy manufacturing and contract services industry

To order this 550+ page report, which features 160+ figures and 250+ tables, please visit this –

The USD 11 billion (by 2030) financial opportunity within the cell therapy manufacturing market has been analyzed across the following segments:
 Type of therapy
 T-cell therapies (CAR-T therapies, TCR therapies, TIL therapies)
 Dendritic cell therapies
 Tumor cell therapies
 NK cell therapies
 Stem cell therapies

 Source of cells
 Autologous
 Allogeneic

 Scale of operation
 Clinical
 Commercial

 Purpose of manufacturing
 Contract manufacturing
 In-house manufacturing

 Key geographical regions
 North America
 Europe
 Asia Pacific
 Rest of the world

The Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030 report features the following companies, which we identified to be key players in this domain:
 BioNTech Innovative Manufacturing Services
 Cell Therapies
 Cell and Gene Therapy Catapult
 Center for Cell and Gene Therapy, Baylor College of Medicine
 Centre for Cell Manufacturing Ireland, National University of Ireland
 Clinical Cell and Vaccine Production Facility, University of Pennsylvania
 Cognate BioServices
 Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
 Hitachi Chemical
 KBI Biopharma
 Laboratory for Cell and Gene Medicine, Stanford University
 Lonza
 MaSTherCell

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Leave a Reply

Your email address will not be published. Required fields are marked *